StonvexLoading…
StonvexStonvexStonvexQuiet session — no dominant driver
Research only. Labels above describe the current state of the stock using price, volume, and news data — they are not buy or sell recommendations. Stonvex is not a registered investment advisor. Past market behavior does not imply future results.
What you need to know right now
This is an algorithmic assessment of current technical conditions, not investment advice. Past performance does not guarantee future results.
Real-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-07 | $2.32 | $2.27 | -2.16% | 5.7M |
| 05-08 | $2.29 | $2.28 | -0.44% | 4.5M |
| 05-11 | $2.29 | $2.28 | -0.44% | 4.5M |
| 05-12 | $2.29 | $2.30 | +0.44% | 10.0M |
| 05-13 | $2.31 | $2.33 | +0.87% | 6.5M |
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
No sell-side coverage available for ALLO.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Metric | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 | Q1 2025 2025-03-31 |
|---|---|---|---|---|
Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
Operating Income | $-209.31M | $-166.91M | $-122.01M | $-65.19M |
Net Income | $-190.89M | $-152.08M | $-50.94M | $-59.73M |
EPS (Diluted) | $-0.87 | $-0.70 | $-0.51 | $-0.28 |
Total Assets | $415.90M | $439.77M | $470.59M | $507.98M |
Total Liabilities | $123.36M | $124.44M | $126.03M | $122.59M |
Cash & Equivalents | $51.69M | $37.81M | $52.33M | $42.45M |
Free Cash Flow OCF − CapEx | $-149.63M | $-122.03M | $-92.10M | $-53.03M |
Shares Outstanding | 229.41M | 223.16M | 220.13M | 218.60M |
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
Fundamentals not available for ALLO.
No fundamental metrics available yet for this ticker — common for ETFs, foreign issuers without US listing depth, very recent IPOs, or thinly-traded OTC names. The Financials tab pulls from SEC EDGAR directly and may still have data.
Press releases, AI summaries, and links to free transcript sources. Audio webcasts live on the issuer's IR site.
Press releases served direct from sec.gov. Stonvex doesn't host transcript bodies — these require the publisher's terms.